Endocrine Causes of Hypertension-Aldosterone

Comprehensive Clinical Nephrology: Fourth Edition

Volumn , Issue , 2010, Pages 469-476

  Weiner, I David ^a   Wingo, Charles S ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882849194     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-05876-6.00038-1     Document Type: Chapter

References (35)

1. Quinn SJ, Williams GH Regulation of aldosterone secretion. Annu Rev Physiol 1988, 50:409-426.
2. Spat A, Hunyady L Control of aldosterone secretion: A model for convergence in cellular signaling pathways. Physiol Rev 2004, 84:489-539.
3. Verlander JW, Hassell KA, Royaux IE, et al. Deoxycorticosterone upregulates PDS (Slc26a4) in mouse kidney: Role of pendrin in mineralocorticoid-induced hypertension. Hypertension 2003, 42:356-362.
4. Kim GH, Masilamani S, Turner R, et al. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci USA 1998, 95:14552-14557.
5. Blazer-Yost BL, Liu X, Helman SI Hormonal regulation of ENaCs: Insulin and aldosterone. Am J Physiol 1998, 274:C1373-C1379.
6. Wingo CS, Kokko JP, Jacobson HR Effects of in vitro aldosterone on the rabbit cortical collecting tubule. Kidney Int 1985, 28:51-57.
7. Bia MJ, DeFronzo RA Extrarenal potassium homeostasis. Am J Physiol 1981, 240:F257-F268.
8. Finch L, Haeusler G Vascular resistance and reactivity in hypertensive rats. Blood Vessels 1974, 11:145-158.
9. Berecek KH, Stocker M, Gross F Changes in renal vascular reactivity at various stages of deoxycorticosterone hypertension in rats. Circ Res 1980, 46:619-624.
10. Nishizaka MK, Zaman MA, Green SA, et al. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857-2861.
11. Gomez-Sanchez EP Brain mineralocorticoid receptors: Orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens 2004, 13:191-196.
12. Gumz ML, Popp MP, Wingo CS, Cain BD Early transcriptional effects of aldosterone in a mouse inner medullary collecting duct cell line. Am J Physiol Renal Physiol 2003, 285:F664-F673.
13. Fuller PJ, Young MJ Mechanisms of mineralocorticoid action. Hypertension 2005, 46:1227-1235.
14. Rogerson FM, Fuller PJ Mineralocorticoid action. Steroids 2000, 65:61-73.
15. Funder JW Non-genomic actions of aldosterone: Role in hypertension. Curr Opin Nephrol Hypertens 2001, 10:227-230.
16. Funder JW The nongenomic actions of aldosterone. Endocr Rev 2005, 26:313-321.
17. Ganguly A Primary aldosteronism. N Engl J Med 1998, 339:1828-1834.
18. Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: A clue to efficient treatment. J Hypertens 2004, 22:2217-2226.
19. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161-165.
20. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after "non-selective" screening of hypertensive patients. J Hypertens 2003, 21:2149-2157.
21. Seiler L, Rump LC, Schulte-Monting J, et al. Diagnosis of primary aldosteronism: Value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004, 150:329-337.
22. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002, 40:897-902.
23. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
24. Young WF Primary aldosteronism: Renaissance of a syndrome. Clin Endocrinol (Oxf) 2007, 66:607-618.
25. Ulick S, Blumenfeld JD, Atlas SA, et al. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab 1993, 76:873-878.
26. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
27. Pascoe L, Curnow KM, Slutsker L, et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992, 89:8327-8331.
28. Weinberger MH, Grim CE, Hollifield JW, et al. Primary aldosteronism. Diagnosis, localization, and treatment. Ann Intern Med 1979, 90:386-395.
29. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: Factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135:258-261.
30. Meyer A, Brabant G, Behrend M Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 2005, 29:155-159.
31. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987, 60:820-825.
32. Lim PO, Young WF, Macdonald TM A review of the medical treatment of primary aldosteronism. J Hypertens 2001, 19:353-361.
33. Epstein M Aldosterone blockade: An emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119:912-919.
34. Lakkis J, Lu WX, Weir MR RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003, 5:408-417.
35. Sato A, Hayashi K, Naruse M, Saruta T Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003, 41:64-68.